期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 127, 期 4, 页码 1254-1270出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI88845
关键词
-
资金
- NIH [AA022614, DK099205, DK101737, DK111866, AA011999, ES010337, AA021856, GM041804]
- Japanese Ministry of Health, Labour and Welfare
- American Liver Foundation
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
Cholestatic liver fibrosis is caused by obstruction of the biliary tract and is associated with early activation of portal fibroblasts (PFs) that express Thy-1, fibulin 2, and the recently identified marker mesothelin (MSLN). Here, we have demonstrated that activated PFs (aPFs) and myofibroblasts play a critical role in the pathogenesis of liver fibrosis induced by bile duct ligation (BDL). Conditional ablation of MSLN+ aPFs in BDL-injured mice attenuated liver fibrosis by approximately 50%. Similar results were observed in MSLN-deficient mice (Msln(-/-) mice) or mice deficient in the MSLN ligand mucin 16 (Muc16(-/-) mice). In vitro analysis revealed that MSLN regulates TGF-beta 1-inducible activation of WT PFs by disrupting the formation of an inhibitory Thy-1-TGF beta RI complex. MSLN also facilitated the FGF-mediated proliferation of WT aPFs. Therapeutic administration of anti-MSLN-blocking Abs attenuated BDL-induced fibrosis in WT mice. Liver specimens from patients with cholestatic liver fibrosis had increased numbers of MSLN+ aPFs/myofibroblasts, suggesting that MSLN may be a potential target for antifibrotic therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据